It is with great pleasure that today, LSP – the specialist European healthcare investment firm – announces that its portfolio company Prosensa was successfully listed on the Nasdaq stock exchange on Friday June 28th under the ticker ''RNA'' at a market capitalization of USD 442 mln, with LSP holding 18% of all shares. On the first trading days, the stock price increased by 48%. LSP was the company’s lead founding investor 6 years ago and remains to be one of the company’s largest shareholders.

Over the years, Prosensa was financed and supported by LSP around the belief that Prosensa’s proprietary technology would allow the development of novel RNA-based therapeutics to address unmet medical needs for patients with certain genetic disorders. With a current clinical development pipeline that includes a number of such products, the most advanced one being in the final stages of development for the treatment of Duchenne Muscular Dystrophy, we are proud to see that belief become a reality. Importantly, the Prosensa investment further validates LSP’s long-term approach of identifying break-through technologies, building companies around them and playing an active role all along. Martijn Kleijwegt has represented LSP on the company’s Board and has worked closely with management and other Board members to steer Prosensa towards this important event in the history of the company.

LSP’s recent exits of Okairos to GSK (where we were also founding lead investor some 6 years ago), of Movetis to Shire (where we have structured the company, put together the first financing syndicate and arranged the IPO), U3 Pharma to Daiichi Sankyo (where we invested in a preclinical asset) and Pasteuria to Syngenta (where we were the largest shareholder and invested in a very early stage) have already confirmed the “early” philosophy. Other recent successes of LSP include the sale of Flowcardia to Bard, BMEYE to Edwards, Kudos to AstraZeneca and Jerini to Shire, as well as the IPO of Zealand Pharma. These exits have allowed the growth of LSP as a firm. Since inception, LSP has launched a number funds, follow-on funds and new products, raising in excess of USD 1 billion of investment capital to date. Most recently, LSP launched its Health Economics Fund, which targets investments in cost-efficient medical technology companies. Other successful investment strategies include LSP’s public healthcare investment activity that has generated triple figure returns over a five year period. As a consequence, LSP has grown to become one of the most successful global healthcare investment groups. « back to overview